Biophytis SA ( (FR:ALBPS) ) has issued an announcement.
Biophytis has entered into a co-development agreement with AskHelpU, China’s largest ALS patient association, to evaluate the effectiveness of its drug candidate BIO101 for treating amyotrophic lateral sclerosis (ALS). This partnership will leverage Biophytis’s expertise in drug development and AskHelpU’s strength in patient-centered research, marking a significant opportunity for Biophytis to expand its reach in the ALS treatment market. The collaboration could potentially offer a therapeutic solution for ALS, a severe neurodegenerative disease affecting thousands globally, with a particularly high prevalence in China.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. The company is developing its main drug candidate, BIO101, for various conditions such as muscular diseases like sarcopenia and Duchenne muscular dystrophy, respiratory diseases like Covid-19, and metabolic diseases like obesity. Biophytis is headquartered in Paris, France, and has subsidiaries in Cambridge, Massachusetts, USA, and Brazil.
YTD Price Performance: -17.71%
Average Trading Volume: 2,030
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €2.57M
Learn more about ALBPS stock on TipRanks’ Stock Analysis page.